Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.

It’s back to school for biotech, with a packed conference schedule.

Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.